Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Part B and C added per protocol amendment (May 2024) Added Part B to explore higher dose levels and Part C to explore effects of food. Part D added per protocol amendment (June 2024) to explore higher multiple doses.
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Male and female participants who are overtly healthy as determined by medical history, vital signs, and physical examination.
Participants of Japanese, Chinese, and Non-Asian ethnicities
Have a body mass index within the range of 18.0 to 32 kilograms per square meter (kg/m²). For healthy Japanese participants, have a body mass index of 18.0 to 28.0 kg/m²
Have venous access sufficient to allow for blood sampling
Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
You may not be if
Have a current or recent acute, active infection
Had any surgical procedure within 12 weeks prior to study
Are immunocompromised
Have presence of significant uncontrolled cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neurologic or neuropsychiatric disorders or abnormal laboratory values
Are currently enrolled in a clinical study involving any experimental antibody or biologic therapy within the previous 6 months, or any other experimental therapy within 30 days before the first dose of the study intervention or during the study
